uniQure (NASDAQ:QURE) Issues Quarterly Earnings Results

uniQure (NASDAQ:QURE) issued its earnings results on Monday. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53), Zacks reports. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. The company had revenue of $3.70 million during the quarter, compared to analyst estimates of $4.46 million.

uniQure Stock Performance

Shares of QURE traded down $1.64 during trading hours on Monday, reaching $26.16. 2,553,553 shares of the company’s stock traded hands, compared to its average volume of 2,210,103. The firm has a market capitalization of $1.44 billion, a price-to-earnings ratio of -6.67 and a beta of 0.59. The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 9.98. The business’s fifty day simple moving average is $42.07 and its two-hundred day simple moving average is $24.30. uniQure has a twelve month low of $5.50 and a twelve month high of $71.50.

Insider Activity at uniQure

In other news, Director Jack Kaye sold 38,810 shares of the company’s stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $30.34, for a total value of $1,177,495.40. Following the completion of the sale, the director owned 20,439 shares in the company, valued at $620,119.26. This represents a 65.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Matthew C. Kapusta sold 226,316 shares of the firm’s stock in a transaction dated Wednesday, September 24th. The shares were sold at an average price of $41.46, for a total value of $9,383,061.36. Following the transaction, the chief executive officer directly owned 651,454 shares of the company’s stock, valued at $27,009,282.84. This represents a 25.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 283,126 shares of company stock worth $11,505,677 over the last quarter. 4.79% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On uniQure

Several hedge funds have recently made changes to their positions in the business. Tower Research Capital LLC TRC lifted its holdings in shares of uniQure by 358.0% during the second quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 5,538 shares during the last quarter. Corient Private Wealth LLC boosted its position in uniQure by 100.0% during the second quarter. Corient Private Wealth LLC now owns 21,260 shares of the biotechnology company’s stock valued at $296,000 after purchasing an additional 10,630 shares during the last quarter. Envestnet Asset Management Inc. bought a new stake in shares of uniQure in the 3rd quarter valued at approximately $674,000. Shay Capital LLC grew its position in uniQure by 21.4% in the second quarter. Shay Capital LLC now owns 99,383 shares of the biotechnology company’s stock worth $1,385,000 after acquiring an additional 17,534 shares in the last quarter. Finally, Militia Capital Partners LP bought a new stake in uniQure in the second quarter worth $309,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Analysts Set New Price Targets

QURE has been the subject of a number of research reports. The Goldman Sachs Group decreased their price target on uniQure from $56.00 to $38.00 and set a “neutral” rating for the company in a research note on Tuesday, November 4th. Benchmark reiterated a “buy” rating on shares of uniQure in a research report on Tuesday, November 4th. William Blair downgraded uniQure from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 4th. Leerink Partners raised their price objective on uniQure from $48.00 to $68.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 24th. Finally, UBS Group set a $95.00 price objective on shares of uniQure in a report on Thursday, September 25th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, uniQure currently has an average rating of “Moderate Buy” and a consensus target price of $66.75.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.